Reveal-Dx
Overview
Reveal-Dx is a Seattle-based innovative software company focused on enhancing lung cancer diagnosis via non-invasive methods. Established in 2014 by Chris Wood and Michael Calhoun, Reveal-Dx aims to improve lung cancer outcomes through its advanced radiomics and AI-enabled decision-support software. The company has raised approximately $4.2 million in funding and continues to expand its influence in the medical diagnostics field.
Recent Developments
- April 2025: Reveal-Dx announced a partnership with contextflow, combining their technology with contextflow's SEARCH solution to enhance lung cancer detection and triage. This collaboration aims to compete with established solutions in the market by offering a comprehensive AI-driven lung screening program.
- October 2024: Reveal-Dx partnered with Riverain Technologies to integrate their products for better lung cancer detection. This partnership enhances their screening capabilities across new regions such as Canada.
- July 2024: The company secured $4.25 million in a Series A funding round, which was instrumental in advancing its radiomics software and expanding its market reach.
- September 2021: A strategic relationship was formed with Volpara Health to enhance lung screening capabilities in the U.S., Australia, and New Zealand. Volpara uses RevealDx’s technology to improve early diagnosis and reduce false positives in lung cancer screenings.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2014 |
| Headquarters | Seattle, WA, USA |
| Founders | Chris Wood, Michael Calhoun |
| Revenue | Approximately $1 million |
| Profits | Not publicly disclosed |
| Key Investors | A-Level Capital, Frost Data Capital |
| Industry | Medical Imaging & Software |
| Number of Employees | Approximately 8-14 |
Early History
Reveal-Dx began its journey in the medical diagnostics realm, inspired by the need to provide non-invasive diagnostic solutions for lung cancer—a disease often diagnosed late due to the invasive nature of traditional biopsy methods. Starting as Mindshare Medical, the company rebranded in 2021 following its acquisition by Precision Medical Ventures. Michael Calhoun, an innovative force in imaging science, brought a wealth of experience and a suite of patented algorithms to the newly named Reveal-Dx, facilitating an early focus on integrating advanced AI with radiomics to interpret CT lung scans more effectively.
Company Profile and Achievements
Reveal-Dx specializes in AI-driven radiomics aimed at improving lung cancer diagnosis. Its key product, RevealAI-Lung, uses machine learning to enhance the characterization of lung nodules seen in CT scans, helping physicians make more accurate decisions. Major achievements include:
- Product Launches: RevealAI-Lung gained CE and Health Canada approvals, allowing its use in several international markets.
- Strategic Partnerships: Collaborations with companies like Riverain Technologies and Volpara Health have expanded Reveal-Dx's technological reach and market penetration.
- Innovative Solutions: The company's products reduce unnecessary procedures by improving diagnostic accuracy, thus also decreasing healthcare costs.
Current Operations and Market Position
As of 2025, Reveal-Dx operates at the intersection of cutting-edge software development and healthcare solutions, focusing particularly on improving lung cancer diagnosis through advanced AI and radiomic technologies. The company holds a competitive edge by providing solutions that integrate seamlessly with existing medical imaging infrastructures like PACS systems. It offers significant market advantages with products like RevealAI-Lung, which can efficiently differentiate benign from malignant nodules, thereby boosting early cancer detection rates.
Conclusion
Reveal-Dx holds a significant position in redefining lung cancer diagnostics through non-invasive techniques that leverage the latest in AI and machine learning. By focusing on innovative partnerships and expanding its market reach, especially in regions like North America and Europe, Reveal-Dx is poised to continue its impact on diagnostic efficiency and accuracy. Its contributions are expected to not only elevate diagnostic practices but also drive down costs associated with lung cancer management, positioning it as a trailblazer in the shift towards precision medicine.